The offer of vaccines against Covid-19 is expanding with the marketing of the Novavax vaccine. It will be available in the Northern Islands at the beginning of March.
This vaccine is based on a technology well known in the world, different from the messenger RNA vaccines recommended and which are currently available in Guadeloupe (Pfizer, Moderna). It uses a protein made in the laboratory, protein S, which allows the virus to enter the human cell. It is the injection of this product directly into the body that will stimulate our defense system by producing protective antibodies. Thus, our body will recognize and fight the virus if we are infected.
The Haute Autorité de Santé specifies that Novavax is indicated primarily in people over 18 years of age who have not yet received any dose of vaccine before. It is administered in two doses intramuscularly spaced 3 weeks apart.
Novavax has shown good efficacy against symptomatic forms of infection 7 days after the 2nd injection and in particular on severe forms of Covid-19.
This vaccine is well tolerated; the adverse effects observed in some people are classic (pain at the injection site, fatigue, headaches, etc.), not very intense and generally disappearing within 24 to 48 hours.
Novavax can also be given to people who have received a first dose of another COVID vaccine and who refuse or cannot receive a 2nd dose of the same vaccine.
HAS recommends the use of messenger RNA vaccines for the vaccination of pregnant women.
Novavax should be available in Guadeloupe, Saint-Martin and Saint-Barthélemy from the beginning of March in vaccination centers and from liberal health professionals via pharmacists.
8,164 total views
No comments